Ónæmiseftirlitshemlar eru flokkur lyfja sem berjast við ónæmiskerfi líkamans til að berjast gegn krabbameinsfrumum. Hins vegar svara flestir sjúklingar ekki þessum meðferðum. Það er til nýrri flokkur lyfja sem miðar að tveimur próteinum sem taka þátt í að bæla ónæmissvörun líkamans gegn æxlum.
Phase I of clinical trials has shown some exciting results, which were conducted in 19 patients suffering from krabbamein with the molecule M7824. These researchers are also undertaking trials with those suffering from briskrabbamein and those infected with HPV.
There are many other trials and experiments being taken to treat and lækna krabbamein more effectively in different research institutes. This drug with a dual approach will be a boon in the meðferð krabbameins, as with a single molecule, multiple therapies are included.